@Article{Wiśniewska-Jarosińska2009,
journal="Gastroenterology Review/Przegląd Gastroenterologiczny",
issn="1895-5770",
volume="4",
number="5",
year="2009",
title="Long-term infliximab treatment in a patient with fistualizing Crohn\’s disease",
abstract="Introduction in the last decade the biological treatment directed against anti-TNF-\α for Crohn\’s disease improved the effectiveness of the therapy and at the same time increased the percentage of clinical remissions achieved. Anti-TNF-\α therapies favourable affect clinical symptoms and reduce the inflammatory indices of the disease. However, the long-term biological treatment carries the risk of the loss of response and adverse events, which sometimes can be very serious. Among these agents, infliximab \– a chimeric, mouse and human, monoclonal antibody, has been used in the treatment of active Crohn\’s disease for the longest time. Presenting  a case report of a young woman with fistualizing Crohn\’s disease the authors want to share their experience and point out the therapeutic problems, which can arise during the long-term biological treatment with anti-TNF-\α agents.",
author="Wiśniewska-Jarosińska, Maria
and Wichan, Paweł
and Chojnacki, Jan",
pages="277--281",
url="https://www.termedia.pl/Long-term-infliximab-treatment-in-a-patient-with-fistualizing-Crohn-8217-s-disease,41,13596,1,1.html"
}